545 related articles for article (PubMed ID: 21377916)
41. Interleukin-6, A Cytokine Critical to Mediation of Inflammation, Autoimmunity and Allograft Rejection: Therapeutic Implications of IL-6 Receptor Blockade.
Jordan SC; Choi J; Kim I; Wu G; Toyoda M; Shin B; Vo A
Transplantation; 2017 Jan; 101(1):32-44. PubMed ID: 27547870
[TBL] [Abstract][Full Text] [Related]
42. Regulation of Interleukin-6 Receptor Signaling by TNF Receptor-Associated Factor 2 and 5 During Differentiation of Inflammatory CD4
Nagashima H; Ishii N; So T
Front Immunol; 2018; 9():1986. PubMed ID: 30214449
[TBL] [Abstract][Full Text] [Related]
43. The role of interleukin-6 signalling and its therapeutic blockage in skewing the T cell balance in rheumatoid arthritis.
Schinnerling K; Aguillón JC; Catalán D; Soto L
Clin Exp Immunol; 2017 Jul; 189(1):12-20. PubMed ID: 28369786
[TBL] [Abstract][Full Text] [Related]
44. Interleukin-6: Biology, signaling and strategies of blockade.
Schaper F; Rose-John S
Cytokine Growth Factor Rev; 2015 Oct; 26(5):475-87. PubMed ID: 26189695
[TBL] [Abstract][Full Text] [Related]
45. Interleukin-17: a new paradigm in inflammation, autoimmunity, and therapy.
Kramer JM; Gaffen SL
J Periodontol; 2007 Jun; 78(6):1083-93. PubMed ID: 17539723
[TBL] [Abstract][Full Text] [Related]
46. Loss of CD4+ T cell IL-6R expression during inflammation underlines a role for IL-6 trans signaling in the local maintenance of Th17 cells.
Jones GW; McLoughlin RM; Hammond VJ; Parker CR; Williams JD; Malhotra R; Scheller J; Williams AS; Rose-John S; Topley N; Jones SA
J Immunol; 2010 Feb; 184(4):2130-9. PubMed ID: 20083667
[TBL] [Abstract][Full Text] [Related]
47. Evidence for the role of Th17 cell inhibition in the prevention of autoimmune diseases by anti-interluekin-6 receptor antibody.
Mihara M; Ohsugi Y; Kishimoto T
Biofactors; 2009; 35(1):47-51. PubMed ID: 19319845
[TBL] [Abstract][Full Text] [Related]
48. gp130 at the nexus of inflammation, autoimmunity, and cancer.
Silver JS; Hunter CA
J Leukoc Biol; 2010 Dec; 88(6):1145-56. PubMed ID: 20610800
[TBL] [Abstract][Full Text] [Related]
49. Targeting classical IL-6 signalling or IL-6 trans-signalling in depression?
Maes M; Anderson G; Kubera M; Berk M
Expert Opin Ther Targets; 2014 May; 18(5):495-512. PubMed ID: 24548241
[TBL] [Abstract][Full Text] [Related]
50. Master regulator of intestinal disease: IL-6 in chronic inflammation and cancer development.
Waldner MJ; Neurath MF
Semin Immunol; 2014 Feb; 26(1):75-9. PubMed ID: 24447345
[TBL] [Abstract][Full Text] [Related]
51. Interleukin-6 trans-signaling and colonic cancer associated with inflammatory bowel disease.
Rose-John S; Mitsuyama K; Matsumoto S; Thaiss WM; Scheller J
Curr Pharm Des; 2009; 15(18):2095-103. PubMed ID: 19519447
[TBL] [Abstract][Full Text] [Related]
52. Enhanced T cell responses to IL-6 in type 1 diabetes are associated with early clinical disease and increased IL-6 receptor expression.
Hundhausen C; Roth A; Whalen E; Chen J; Schneider A; Long SA; Wei S; Rawlings R; Kinsman M; Evanko SP; Wight TN; Greenbaum CJ; Cerosaletti K; Buckner JH
Sci Transl Med; 2016 Sep; 8(356):356ra119. PubMed ID: 27629486
[TBL] [Abstract][Full Text] [Related]
53. Hitting a complex target: an update on interleukin-6 trans-signalling.
Waetzig GH; Rose-John S
Expert Opin Ther Targets; 2012 Feb; 16(2):225-36. PubMed ID: 22324903
[TBL] [Abstract][Full Text] [Related]
54. Il-6 signaling in inflammatory bowel disease: pathophysiological role and clinical relevance.
Mudter J; Neurath MF
Inflamm Bowel Dis; 2007 Aug; 13(8):1016-23. PubMed ID: 17476678
[TBL] [Abstract][Full Text] [Related]
55. IL-12-and IL-23 in health and disease.
Croxford AL; Kulig P; Becher B
Cytokine Growth Factor Rev; 2014 Aug; 25(4):415-21. PubMed ID: 25130295
[TBL] [Abstract][Full Text] [Related]
56. The Role of Flavonoids in Inhibiting Th17 Responses in Inflammatory Arthritis.
Kelepouri D; Mavropoulos A; Bogdanos DP; Sakkas LI
J Immunol Res; 2018; 2018():9324357. PubMed ID: 29693024
[TBL] [Abstract][Full Text] [Related]
57. Interleukin-6, its role in fibrosing conditions.
O'Reilly S; Ciechomska M; Cant R; Hügle T; van Laar JM
Cytokine Growth Factor Rev; 2012 Jun; 23(3):99-107. PubMed ID: 22561547
[TBL] [Abstract][Full Text] [Related]
58. IL-6, IL-17 and STAT3: a holy trinity in auto-immunity?
Camporeale A; Poli V
Front Biosci (Landmark Ed); 2012 Jun; 17(6):2306-26. PubMed ID: 22652781
[TBL] [Abstract][Full Text] [Related]
59. Inhibition of the IL-6 signaling pathway: a strategy to combat chronic inflammatory diseases and cancer.
Ataie-Kachoie P; Pourgholami MH; Morris DL
Cytokine Growth Factor Rev; 2013 Apr; 24(2):163-73. PubMed ID: 23107589
[TBL] [Abstract][Full Text] [Related]
60. Therapeutic targeting of the interleukin-6 receptor.
Tanaka T; Narazaki M; Kishimoto T
Annu Rev Pharmacol Toxicol; 2012; 52():199-219. PubMed ID: 21910626
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
